MedTrace Logo

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

NCT00007423 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe to give ALVAC-HIV vCP205, a possible HIV vaccine, and to study the immune responses in adult HIV-1 uninfected volunteers.

Uganda has been severely affected by HIV infection and AIDS and has been selected to participate in HIV-vaccine development. The HIV viruses commonly isolated from Uganda are 2 kinds that are not used in making current vaccines. Current vaccines generate several kinds of immune responses. Researchers would like to see if a response to the kind of virus in a current vaccine will also protect people from the viruses commonly found in Uganda.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

Sponsors & Collaborators

  • Joint Clinical Research Center

    collaborator OTHER

  • MRC/UVRI and LSHTM Uganda Research Unit

    collaborator OTHER

  • Joint UN Programme on HIV/AIDS (UNAIDS)

    collaborator OTHER

  • Fogarty International Center of the National Institute of Health

    collaborator NIH

  • Case Western Reserve University

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Roy Mugerwa

  • Jerrold Ellner

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Completion
2001-09-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00007423 on ClinicalTrials.gov